Results for tag: "Elafibranor"

Elafibranor is a drug used to treat Gastrointestinal (GI) diseases. It is a selective agonist of the peroxisome proliferator-activated receptor alpha (PPARα) and is used to treat nonalcoholic steatohepatitis (NASH). Elafibranor is a promising treatment for NASH, as it has been shown to reduce liver fat, improve liver function, and reduce inflammation. It is also being studied for its potential to reduce the risk of cardiovascular disease in NASH patients. Elafibranor is currently in Phase III clinical trials and is expected to be approved by the US Food and Drug Administration (FDA) in 2021. It is being developed by Genfit, a French biopharmaceutical company, and is being evaluated in several countries around the world. Other companies involved in the development of Elafibranor include Intercept Pharmaceuticals, Allergan, and Novartis. Show Less Read more